The 3 Things That Matter for Pfizer Now

Once a market darling during the early pandemic years, Pfizer (NYSE: PFE) has been on a straight southbound path for several years now. The company's shares are down by 50% since 2022.Some investors might see this as an opportunity to buy the stock on the dip, but that'd only be a good move if there are excellent reasons to think the stock might bounce back. There are several things investors can watch out for to determine this. Let's consider three of the most important.Any struggling pharmaceutical company will try to turn things around by developing newer medicines. Pfizer is no exception; its pipeline is deep, with over 100 active programs. The drugmaker is particularly focused on making a significant impact in the oncology market, one of the largest segments in the industry. That's why Pfizer spent $43 billion to acquire Seagen, a smaller biotech that specialized in oncology.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool